McDavid Stilwell - 31 Dec 2023 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Reporting relationship: Chief Financial Officer
Issuer ticker: CHRS
Reported as of: 31 Dec 2023
Net transaction value: -$61,405
SEC form: 4
Accepted by SEC: 03 Jan 2024, 16:42:10 UTC
Prior SEC filing: 15 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Bryan McMichael, as Attorney-in-Fact for McDavid Stilwell

Filing notes and source

Key filing fact

McDavid Stilwell filed Form 4 for Coherus BioSciences, Inc. (CHRS) on 03 Jan 2024.

Key facts

This page summarizes McDavid Stilwell's Form 4 filing for Coherus BioSciences, Inc. (CHRS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Jan 2024, 16:42.

Change

Previous filing in this sequence was filed on 15 Jun 2023.
Current net transaction value: -$61,405.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CHRS transaction

Common Stock

Tax liability

Transaction value: $61,405
Shares: -18,440
Change %: -20%
Price: $3.33
Shares after: 75,305
Date: 31 Dec 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3.

Footnote F2

Includes 4,826 shares acquired on November 15, 2023, pursuant to the Coherus BioSciences, Inc. Employee Stock Purchase Plan and includes the cancellation of 13,333 restricted stock units.